Stemedica Cell Technologies, Inc. services

Coronavirus disease 2019 (COVID-19) is a respiratory illness that can spread from person to person. This is a novel (or new) coronavirus that has not previously been seen in humans which has a wide range of symptoms reported with certain patients experiencing shortness of breath or difficulty breathing.

Every year in the United States alone, almost 800,000 people suffer a stroke. Of that number, more than 137,000 will die from a stroke, making it the third highest cause of death in the United States. Eighty-seven percent of all strokes are ischemic, which are caused by blood clots.* Stemedica has completed a Phase I/IIA clinical trial to assess the safety and efficacy  of using adult bone-marrow derived mesenchymal stem cells for ischemic stroke patients.

Stemedica has licensed the exclusive, global distribution rights for the ischemic tolerant mesenchymal stem cell (itMSC) and ischemic tolerant neural stem cell (itNSC) products to Life Technologies for research purposes only. In 2014, Life Technologies was acquired by ThermoFisher Scientific. ThermoFisher Scientific now markets the itMSC and itNSC products under its own private label: StemPro® Neural Stem Cells and StemPro® Mesenchymal Stem Cells. All cells sold to ThermoFisher Scientific by Stemedica are produced under cGMP manufacturing standards at Stemedica’s California-licensed facility and are restricted only for pre-clinical purposes.

In 2016 alone, the United States spent $236 billion fighting Alzheimer’s disease and other forms of dementia. More than five million Americans are currently living with Alzheimer’s disease, and it is the sixth-leading cause of death across all ages in the United States.* Stemedica is conducting a Phase IIa Multicenter, Randomized, Single blind, Placebo-controlled, Crossover Study to Assess the Safety, Tolerability, and Preliminary Efficacy of a Single Intravenous Dose of Allogeneic Human Mesenchymal Stem Cells in Subjects with Mild to Moderate Dementia Due to Alzheimer’s Disease.